Latest Triptan Stories

MELBOURNE, Australia, Feb. 5, 2013 /PRNewswire/ -- HEADACHES and migraines affect up to 15-20 per cent of the population, and a new survey has been completed, providing valuable insight into relief for sufferers. (Photo: http://photos.prnewswire.com/prnh/20130205/HK53292-INFO) Leading health website headache.com.au has completed a survey which explores the success rates of the various therapeutic approaches according to the type of head pain. The study which ran from June to Dec....

Lawrence LeBlond for redOrbit.com - Your Universe Online Painful headaches that affect nearly a million people in the UK, and many more millions worldwide, may be partly caused by overuse of common painkillers such as aspirin, paracetamol and triptans, according to the National Institute for Health and Clinical Excellence (NICE). The watchdog estimates that one in 50 people who experience headaches are suffering because they overuse their medications. The warning comes as the group,...

Acupuncture shows clinical effect in treating migraines but whether real or placebo effect is uncertain Acupuncture and sham acupuncture appear equally effective in treating migraines, according to a clinical trial published in CMAJ (Canadian Medical Association Journal) (pre-embargo link only) http://www.cmaj.ca/site/embargo/cmaj110551.pdf. An international team of researchers conducted a randomized controlled trial to determine the effect of acupuncture compared with sham acupuncture...

CHICAGO, Oct. 31, 2011 /PRNewswire-USNewswire/ -- The news that actress Tori Spelling was rushed to the hospital with a "horrendous migraine" which occurred a few weeks after the birth of her third child, clearly illustrates the role of hormone fluctuations in migraine headaches. At least 70% of migraine sufferers are women, with the majority relating the acute headaches to hormonal changes, during their menstrual periods, pregnancy, and menopause. Until puberty, the occurrence of...

MOUNTAIN VIEW, Calif., Aug. 2, 2011 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that its New Drug Application (NDA) for LEVADEX® orally inhaled migraine drug for the potential acute treatment of migraine in adults has been accepted for filing by the U.S. Food and Drug Administration (FDA), with a goal date of March 26, 2012 under the Prescription Drug User Fee Act (PDUFA). In accordance with the Company's collaboration agreement with Allergan, Inc., the FDA's...

An inexpensive, hundred-year-old therapy for pain "“ aspirin "“ is effective in high doses for the treatment of severe headache and migraine caused by drug withdrawal, according to a new study by researchers with the UCSF Headache Center.  Study participants were administered aspirin through an IV and 25 percent of the time they reported a significant reduction in pain "“ three points on the 10-point pain scale.  (A difference of three points downgrades a headache from severe to...

Patients with a cluster headache, which is characterized by bouts of excruciating pain usually near the eye or temple, were more likely to report being pain-free within 15 minutes of treatment with high-flow oxygen than patients who received a placebo treatment, according to a study in the December 9 issue of JAMA.Cluster headache attacks typically last for 15 minutes to 3 hours untreated and have a frequency of 1 every other day for up to 8 attacks a day. Attacks usually occur in bouts, or...

MOUNTAIN VIEW, Calif., Dec. 1 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced the appointment of Alan Petro to the newly created position of Vice President, Manufacturing and Technical Operations. In his new role, Mr. Petro will lead the company's efforts in the area of product/process development and manufacturing in order to prepare for the potential commercialization of the company's lead product candidate, LEVADEX(TM) orally inhaled migraine therapy....

MOUNTAIN VIEW, Calif., Nov. 12 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that it has secured a committed equity financing facility under which it may sell up to $60 million of its registered common stock to Azimuth Opportunity Ltd. MAP Pharmaceuticals is not obligated to utilize any of the $60 million facility, which has a term of 24 months. During the term of the purchase agreement, at its sole discretion and subject to certain conditions, MAP...

New Discovery Provides Migraine Relief in Minutes Without Side Effects or Pills PHOENIX and SCOTTSDALE, Ariz., Feb. 5 /PRNewswire/ -- Board-certified neurologist and migraine specialist Morton I. Hyson, M.D., will announce a revolutionary new treatment for migraines and chronic headaches, according to Clinical Topicals PHP. The treatment works in minutes, not hours, without side effects, pills or contraindications (www.HysonHeadache.com). After a decade of research, Dr. Hyson will make...